Health Policy from JAMA Health Forum New Online https://ift.tt/ES8ZYce

This JAMA Forum discusses the complexities of health care policy in the US, unique aspects of health care costs, and the challenges associated with achieving affordable health care for everyone. from JAMA Health Forum New Online https://ift.tt/GLDJrIF

This Viewpoint describes the historical and current exclusion of people with intellectual and developmental disabilities from research and gives recommendations for their equitable inclusion. from JAMA Internal Medicine Online First https://ift.tt/ykVeq5Z

This Viewpoint discusses a new approach to life expectancy by focusing on basic needs met. from JAMA Health Forum New Online https://ift.tt/FRDkSfQ

This JAMA Internal Medicine Patient Page describes sources of information about vaccination and how to know which sources are trustworthy. from JAMA Internal Medicine Online First https://ift.tt/tr3ocXH

This JAMA Forum discusses changes to the Supplemental Nutrition Assistance Program (SNAP) through the budget reconciliation act of 2025 (HR 1), the implications for beneficiaries, and a call to action for health professionals. from JAMA Health Forum New Online https://ift.tt/pKW5LFs

This Viewpoint recommends that patients with actinic keratoses receive active surveillance in primary care rather than routine treatment. from JAMA Internal Medicine Online First https://ift.tt/TnHF14X

This cohort study uses a target trial emulation approach to estimate the effect of enrolling in Supportive Services for Veteran Families on mortality and health care costs in the Veterans Affairs health care system. from JAMA Health Forum New Online https://ift.tt/OPK6I2l

This Viewpoint describes factors necessary to eliminate hepatitis C virus, including access to point-of-care RNA testing and availability of treatment, and the stakeholders from the federal to the community level that must participate. from JAMA Health Forum New Online https://ift.tt/soUaTQL

This JAMA Forum discusses upcoming Supreme Court decisions and the potential damage to public health, including decreases in vaccination rates, in firearms control, and in the rights of sexual minority individuals. from JAMA Health Forum New Online https://ift.tt/VPqXKhd

This comparative effectiveness research study examines whether kidney outcomes differ with sodium-glucose cotransporter-2 (SGLT2) inhibitor vs glucagon-like peptide-1 (GLP-1) receptor agonist treatment in individuals with type 2 diabetes. from JAMA Internal Medicine Online First https://ift.tt/Qt6whNW